Relationship between 4-hydroxyanisole toxicity and dopa oxidase activity for three melanoma cell lines

Melanoma Research

Volumn 7, Issue 5, 1997, Pages 373-381

  Rodriguez Vicente, J ^a   Vicente Ortega, V ^a   Canteras Jordana, M ^a   Calderon Rubiales, F ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

4 hydroxyanisole; B16F10; Cell cultures; Dopa oxidase activity; Electron microscopy; Light microscopy; Melanoma; SK MEL 1; SK MEL 28

Indexed keywords

CATECHOL OXIDASE; MEQUINOL;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME SPECIFICITY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030694236     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199710000-00003     Document Type: Article

References (34)

1. Koh HK. Cutaneous melanoma. N Engl J Med 1991; 325: 171-182.
2. Runkle GP, Zaloznik AJ. Malignant melanoma. Am Family Physician 1994; 49(1): 91-98.
3. Vicente Ortega JJ, Vicente Ortega V, Rodríguez Vicente J, et al. Melanoma cutáneo en la Comunidad Autóno ma de Murcia. Estudio clínico patológico y evolutivo (1971 1990). Patología 1996; 29: 233-241.
4. Hochstein P, Cohen G. The cytotoxicity of melanin precursors. Ann NY Acad Sci 1963; 100: 878-886.
5. Graham DG, Tiffany SM, Vogel SF. The toxicity of melanin precursors. J Invest Dermatol 1978; 70: 113-116.
6. Riley PA. Mechanism of pigment-cell toxicity produced by hydroxyanisole. J Pathol 1970; 101: 163-169.
7. Dewey DL, Butcher FW, Galpine AR. Hydroxyanisole-induced regression of the Harding-Passey melanoma in mice. J Pathol 1977; 122: 117-124.
8. Kanclerz A, Chapman JD. The treatment of animal tumours and their metastases with 4-hydroxyanisole. Br J Cancer 1986; 54: 693-698.
9. Kulkarni GA, Nathanson L. Specificity of growth inhibition of melanoma by 4-hydroxyanisole. Pigment Cell Res 1989; 2: 40-43.
10. Carmichael J, DeGraff WG, Gazdar A, et al. Evaluation of a tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-942.
11. Carmichael J, DeGraff WB, Gazdar AF, et al. Evaluation of tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 1987; 47: 943-946.
12. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589-601.
13. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150: 76-85.
14. Winder AJ, Harris H. New assays for the tyrosine hydroxylase and dopa oxidase activities of tyrosinase. Eur J Biochem 1991; 198: 317-326.
15. Smit NP, Latter AJ, Naish Byneld S, et al. Catechol-O-methyltransferase as a target for melanoma destruction? Biochem Pharmacol 1994; 48: 743-752.
16. Prezioso JA, Epperly MW, Wang N, et al. Effects of tyrosinase activity on the cytotoxicity of 4-S-cysteaminylphenol and N-acetyl-4-S-cysteaminylphenol in melanoma cells. Cancer Lett 1992; 63(1): 73-79.
17. Naish-Byfield S, Cooksey CJ, Latter AM, et al. In vitro assessment of the structure-activity relatioship of tyrosinase-dependent cytotoxicity of a series of substituted phenols. Melanoma Res 1991; 1(4): 27.3-289.
18. Smit NP, Peters K, Menko W, et al. Cytotoxicity of a selected series of substituted phenols towards cultured melanoma cells. Melanoma Res 1992; 2: 295-304.
19. Rustin GJ, Stratford MR, Lamont A, et al. Phase I study of intravenous 4-hydroxyanisole. Eur J Cancer 1992; 28A: 1362-1.364.
20. Belcher HJ, Barsted CG, Dawson CM. 4-Hydroxyanisole: human pharmacokinetics. Pigment Cell Res 1990; 3: 306-309.
21. Scott RN, Kerr DJ, Blackie R, et al. The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma. Br J Cancer 1992; 66: 239-242.
22. Klaase JM, Kroon BBR, Vangeel AN, et al. A retrospective comparative study evaluating the results of a single-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer 1993; 71: 2990-2994.
23. Lee SM, Margison GP, Woodcock AA, et al. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356-1360.
24. Wu L, Smythe AM, Stinson SF, et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines for anticancer drug screening. Cancer Res 1992; 3: 3029-3034.
25. Toshima S, Moore GE, Sandberg AA. Ultrastructure of human melanoma in cell culture: electron microscopic studies. Cancer 1968; 21: 202-216.
26. Vicente V, Gómez M. Gómez S, et al. Thermotherapy for Harding-Passey melanoma: light and electron microscopic study. Histol Histopathol 1987; 2: 369-381.
27. Vicente V, Gómez M, Ochotorena MM, et al. Thermochemotherapy for B16 melanoma: combination therapy of hyperthermia, melphalan, and CCNU in mice. Pigment Cell Res 1990; 3: 1-7.
28. García-Reverte JM, Bernabeu-Esclapez A, Muñoz-Ramos J, et al. Effects of various antineoplastic agents on an established human melanoma cell line (G-361). Histol Histopathol 1995; 10: 79-84.
29. Koga S, Nakamo M, Ito T, et al. Importance of iron in lipid preoxidation in the tyrosinase/4-hydroxyanisole system: possible mechanism of killing of malignant melanoma cells by 4-hydroxyanisole. Biochem Int 1992; 26(3): 397-403.
30. Vicente Ortega V, Martinez Diaz F, Carrascosa Romero C, et al. Abnormal melanosomes: ultrastructural markers of melanocytic atypia. Ultrastruct Pathol 1995; 19: 119-128.
31. Takahashi H, Horikoshi T, Jimbow K. Fine structural characterization of melanosomes in dysplastic nevi. Cancer 1985; 56: 111-123.
32. Pawelek J, Dorner A, Bergstrom A, et al. New regulators of melanin biosynthesis and the auto-destruction of melanoma cells. Nature 1980; 286: 617-619.
33. Körner A, Pawelek J. Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin. Science 1982; 217: 1163-1165.
34. Hearing VJ, Jorner AM, Pawelek JH. New regulators of melanogenesis are associated with purified tyrosinase isozymes. J Invest Dermatol 1982; 79: 16-18.